Emerging drugs for acute lung injury
- 2 January 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Emerging Drugs
- Vol. 20 (1) , 75-89
Abstract
Introduction: Acute respiratory distress syndromes (ARDS) are devastating disorders of overwhelming pulmonary inflammation and hypoxemia, resulting in high morbidity and mortality.Areas covered: Th...Keywords
This publication has 136 references indexed in Scilit:
- Mesenchymal stem cells enhance survival and bacterial clearance in murineEscherichia colipneumoniaThorax, 2012
- A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury*Critical Care Medicine, 2012
- A phase II randomized placebo-controlled trial of omega-3 fatty acids for the treatment of acute lung injury*Critical Care Medicine, 2011
- Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome*Critical Care Medicine, 2011
- Functional Disability 5 Years after Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2011
- Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injuryCritical Care Medicine, 2011
- Beyond Mortality: Future Clinical Research in Acute Lung InjuryAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trialThe Lancet, 2009
- Diabetes, insulin, and development of acute lung injuryCritical Care Medicine, 2009
- Inhaled nitric oxide for acute respiratory distress syndromeBMJ, 2007